Peers
FA Score
DQ Score
close
52 week range
Nordic Nanovector ASA engages in providing Antibody-Radionuclide-Conjugate clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. The Company intends to commercialize its product candidates, and create a differentiated and specific positioning. It develops anticancer therapeutics for haematologic cancers, such as NHL and other B-cell malignancies, characterised by high unmet medical need. It also engages in development of radioimmunotherapeutics that treat cancers using the nanovector targeting technology. Its product Betalutin, which is an antibody-radionuclide-conjugate aims to prolong the survival and improve the quality of life of patients who suffer from non-Hodgkin lymphoma. The company was founded by Roy H. Larsen, Ãyvind S. Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway.
